BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23054648)

  • 21. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
    Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
    J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysregulated EVI1 expression in myeloid malignancies.
    Pardanani A
    Leuk Lymphoma; 2006 Dec; 47(12):2443-4. PubMed ID: 17169788
    [No Abstract]   [Full Text] [Related]  

  • 23. Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literature.
    Agostino NM; Ahmed B; Popescu D; Gheith S
    Int J Clin Exp Pathol; 2011 Mar; 4(3):322-6. PubMed ID: 21487529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
    Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD
    Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26.
    Morishita K; Parganas E; William CL; Whittaker MH; Drabkin H; Oval J; Taetle R; Valentine MB; Ihle JN
    Proc Natl Acad Sci U S A; 1992 May; 89(9):3937-41. PubMed ID: 1570317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes.
    Raynaud SD; Baens M; Grosgeorge J; Rodgers K; Reid CD; Dainton M; Dyer M; Fuzibet JG; Gratecos N; Taillan B; Ayraud N; Marynen P
    Blood; 1996 Jul; 88(2):682-9. PubMed ID: 8695816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EVI1 expression predicts outcome in higher-risk myelodysplastic syndrome patients.
    Liu L; Wang J; Jiang Y; Xie H; Tang X; Li Q; Wang H; Zou P; Miao Z; Lv Y; Wang H; Cao Z; Zhao Z
    Leuk Lymphoma; 2018 Dec; 59(12):2929-2940. PubMed ID: 29846125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
    Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
    Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
    Sitailo S; Sood R; Barton K; Nucifora G
    Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel variant of acute myelomonocytic leukemia carrying t(3;12)(q26;p13) with characteristics of 3q21q26 syndrome.
    Iwase S; Furukawa Y; Horiguchi-Yamada J; Nemoto T; Takahara S; Kawano T; Sekikawa T; Ito K; Yamazaki Y; Kikuchi J; Morishita K; Yamada H
    Int J Hematol; 1998 Jun; 67(4):361-8. PubMed ID: 9695409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26).
    Suzukawa K; Parganas E; Gajjar A; Abe T; Takahashi S; Tani K; Asano S; Asou H; Kamada N; Yokota J
    Blood; 1994 Oct; 84(8):2681-8. PubMed ID: 7919381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome.
    Jaju RJ; Jones M; Boultwood J; Kelly S; Mason DY; Wainscoat JS; Kearney L
    Genes Chromosomes Cancer; 2000 Nov; 29(3):276-80. PubMed ID: 10992302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
    Gröschel S; Sanders MA; Hoogenboezem R; de Wit E; Bouwman BAM; Erpelinck C; van der Velden VHJ; Havermans M; Avellino R; van Lom K; Rombouts EJ; van Duin M; Döhner K; Beverloo HB; Bradner JE; Döhner H; Löwenberg B; Valk PJM; Bindels EMJ; de Laat W; Delwel R
    Cell; 2014 Apr; 157(2):369-381. PubMed ID: 24703711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute panmyelosis with myelofibrosis with EVI1 amplification.
    Grygalewicz B; Woroniecka R; Pastwińska A; Rygier J; Krawczyk P; Borg K; Makuch-Łasica H; Patkowska E; Pieńkowska-Grela B
    Cancer Genet; 2012 May; 205(5):255-60. PubMed ID: 22682625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
    Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
    Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms].
    Tanaka A
    Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
    Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements.
    Poppe B; Dastugue N; Vandesompele J; Cauwelier B; De Smet B; Yigit N; De Paepe A; Cervera J; Recher C; De Mas V; Hagemeijer A; Speleman F
    Genes Chromosomes Cancer; 2006 Apr; 45(4):349-56. PubMed ID: 16342172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.
    Shimada K; Tomita A; Minami Y; Abe A; Hind CK; Kiyoi H; Cragg MS; Naoe T
    Exp Hematol; 2012 Sep; 40(9):724-737.e2. PubMed ID: 22634393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
    Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
    Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.